Unfolding Neurological and Neuropsychiatric
Complications due to Covid-19

About us

The European research project NeuroCOV aims to investigate neurological and neuropsychological complications due to COVID-19. These include a compromised sense of smell and taste, impaired ability to concentrate, memory problems, stroke, and significant brain scan alterations among COVID-19 patients across all ages and independent of COVID-19 severity.

The impact of this phenomenon, also called NeuroCOVID, is immense, and society and healthcare systems are at risk of unprecedented consequences. With a multidisciplinary and international consortium of 10 institutions, NeuroCOV strives to enhance the medical predicaments of developing NeuroCOVID, advance monitoring and treatment, as well as address the societal consequences of this major global problem.

Through the NEUROCOV project, we want to contribute to a better understanding of COVID-19 and the associated NeuroCOVID. Based on this knowledge, we strive to contribute to developing new and effective treatments.

Joachim L. Schultze, German Center for Neurodegenerative Diseases (DZNE)

A distinctive feature of the project is its multi-scale design ranging from socio-economic impact at the population level to the molecular mechanisms underlying individual vulnerabilities to NeuroCOVID. To do this, several highly interdisciplinary teams will study the virus-host interaction by combining brain organoids and high-resolution omics technologies with artificial intelligence to develop predictive models capable of assessing individual risk of developing NeuroCOVID complications and long-term effects.

Giuseppe Testa, Human Technopole

We are excited to help provide NeuroCOV with crucial technologies and biological/bioinformatics expertise to collect and analyse the data generated in the project. Specifically, based on the clinical data and biological samples collected from large cohorts of NeuroCOVID patients, we will contribute to the identification of immunological and neurological alterations responsible for NeuroCOVID. Brought together by this important project, the partners will deepen, from different perspectives, our overall knowledge of NeuroCOVID.

Domenico Mavilio, University of Milan

We are excited to collaborate with NeuroCOV partners and bring our expertise in epidemiology to the consortium. By linking various nation-wide health registers, we are able to investigate the epidemiological characteristics of COVID-19 and its long-term neurological consequences.

Anna-Leena Vuorinen, Institute for Molecular Medicine Finland

As a computational biologist working on basic science, I am excited to be able to contribute to research that can improve the life of many people suffering from Post-COVID neurological symptoms.

Tal Shay, Ben-Gurion University of the Negev

NeuroCOV is an exciting prospect to consolidate expertise from molecular biology to large-scale population data with the aim of gaining answers to the potentially debilitating clinical neurological features following infection with SARS-CoV-2. The hope is that the international expertise will help further exploit large-scale population data and generate new collaborations across borders.

Anne-Marie Fors Connolly, Umeå University

At Helmholtz Munich, we have deep expertise in machine learning and artificial intelligence. As part of the NeuroCOV consortium, we will develop predictive models based on single-cell omics readouts to assess better individual risk of having Post-COVID complications and of their long-term impact. Ultimately, this will lead to better prevention, prognosis, and disease management of COVID-19 patients at a personalised level.

Fabian Theis, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH

01/09/2022 start date
60 month of duration
8,384,036 € Budget
10 partners from 7 countries

News

Open Position | Postdoc - Testa Group @ Human Technopole (Milan, Italy)

Prof. Giuseppe Testa's laboratory at the Human Technopole (HT) in Milan is hiring a Postdoctoral Researcher to contribute to the NeuroCOV project. To...

Open Position | Postdoc - Testa Group @ Human Technopole (Milan, Italy) read more...

NeuroCOV’s First Progress Meeting Held in Milan, Italy

On the 26th and 27th of June, 2023, the first NeuroCOV Progress Meeting took place at Human Technopole in Milan. Following last year’s hybrid Kick-O...

NeuroCOV’s First Progress Meeting Held in Milan, Italy read more...

EU Knowledge Valorisation Week 2023: Learn More on Turning Research into Solutions

Join stakeholders and policymakers at the EU Knowledge Valorisation Week between 25 April and 28 April 2023. The annual event highlights best practice...

EU Knowledge Valorisation Week 2023: Learn More on Turning Research into Solutions read more...

NeuroCOV in the Italian magazine PLATINUM with Il Sole 24 Ore

In the issue of March 2023, the magazine PLATINUM “Aziende & Protagonisti”, attached to the Italian financial newspaper Il Sole 24 Ore, features a...

NeuroCOV in the Italian magazine PLATINUM with Il Sole 24 Ore read more...

Webinar on Patent Protection for EU funding beneficiaries

NeuroCOV invites anyone involved in the field of Artificial Intelligence in medical technology to join the webinar on patent protection on the 16th of...

Webinar on Patent Protection for EU funding beneficiaries read more...

Open Position | Postdoc - Testa Group @ Human Technopole

Prof. Giuseppe Testa's laboratory at the Human Technopole (HT) in Milan is hiring a Postdoctoral Researcher to contribute to the NeuroCOV project. To...

Open Position | Postdoc - Testa Group @ Human Technopole read more...

Open Position | Postdoc - Harschnitz Group @ Human Technopole

Oliver Harschnitz's laboratory at the Human Technopole (HT) in Milan is hiring a Postdoctoral Researcher to contribute to the NeuroCOV project. To lea...

Open Position | Postdoc - Harschnitz Group @ Human Technopole read more...

New Project “NEUROCOV”

New EU Research Project NEUROCOV Investigates Neurological and Neuropsychiatric Complications Following COVID-19 Infections

Over the next five years...

New Project “NEUROCOV” read more...